Global Uveitis Market - 2022-2031

August 2025 | 200 pages | ID: G927138C315AEN
DataM Intelligence

Abstracts

The Global Uveitis Market was valued at US$ 456 million in 2022 and is anticipated to reach US$ 837 million by 2031, at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Uveitis Market.

This report delivers a comprehensive overview of the Global Uveitis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Uveitis Market. The Global Uveitis Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Global Uveitis Market Scope:

By Uveitis Type

• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Pan Uveitis

By Medications

• Corticosteroids
• Anti-Rheumatic Drugs
• Cycloplegic-Mydriatic Drugs
• Immunomodulatory Therapy
• Biological Therapy
• Anti-Viral Drugs
• Others

By Medication Form

• Eye Drops
• Pills
• Injections
• Implants

By End-User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Key Players

• Novartis AG
• AbbVie
• Johnson & Johnson Services, Inc.
• Amgen
• Alimera Sciences
• Bausch & Lomb Incorporated.
• Kiora Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• EyePoint Pharmaceuticals, Inc.
• Clearside Biomedical(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Global Uveitis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Uveitis Market. The Global Uveitis Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing product pipeline of pharma companies
    4.1.1.2. Rising advancements in technologies leading to the development of new drugs
  4.1.2. Restraints:
    4.1.2.1. High cost associated with treatment
    4.1.2.2. High risk of side effects
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion

7. BY UVEITIS TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  7.1.2. Market Attractiveness Index, By Uveitis Type
7.2. Anterior Uveitis *
  7.2.1. Introduction
  7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Intermediate Uveitis
7.4. Posterior Uveitis
7.5. Pan Uveitis

8. BY MEDICATIONS

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids *
  8.2.1. Introduction
  8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  8.2.3. Betamethasone
  8.2.4. Dexamethasone
  8.2.5. Cortisone
  8.2.6. Triamcinolone
  8.2.7. Methylprednisolone
8.3. Anti-Rheumatic Drugs
  8.3.1. Mycophenolate
  8.3.2. Cyclosporine
  8.3.3. Azathioprine
  8.3.4. Tacrolimus
8.4. Cycloplegic-Mydriatic Drugs
  8.4.1. Tropicamide
  8.4.2. Cyclopentolate
  8.4.3. Phenylephrine
  8.4.4. Homatropine
  8.4.5. Atropine
8.5. Immunomodulatory Therapy
  8.5.1. Azathioprine
  8.5.2. Methotrexate
  8.5.3. Mycophenolate Mofetil
  8.5.4. Cyclosporine
8.6. Biological Therapy
  8.6.1. Infliximab
  8.6.2. Adalimumab
  8.6.3. Daclizumab
  8.6.4. Interferon-Alfa
8.7. Anti-Viral Drugs
  8.7.1. Aciclovir
  8.7.2. Valaciclovir
8.8. Others

9. BY MEDICATION FORM

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  9.1.2. Market Attractiveness Index, By Medication Form
9.2. Eye Drops *
  9.2.1. Introduction
  9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Pills
9.4. Injections
9.5. Implants

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospital Pharmacies *
  10.2.1. Introduction
  10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
10.3. Retail Pharmacies
10.4. Online Pharmacies

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. U.K.
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch

13. COMPANY PROFILES

13.1. Novartis AG *
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. AbbVie
13.3. Johnson & Johnson Services, Inc.
13.4. Amgen
13.5. Alimera Sciences
13.6. Bausch & Lomb Incorporated.
13.7. Kiora Pharmaceuticals, Inc.
13.8. Santen Pharmaceutical Co., Ltd.
13.9. EyePoint Pharmaceuticals, Inc.
13.10. Clearside Biomedical(*LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

14.1. Appendix
14.2. About Us and Medications
14.3. Contact Us